Investor
FAQs
Jade Biosciences is headquartered at 221 Crescent Street, Building 23, Suite 105 in Waltham, Massachusetts, 02453.
Jade Biosciences is incorporated in the state of Nevada.
Jade Biosciences’ auditor is PricewaterhouseCoopers LLP.
Jade Biosciences’ fiscal year ends on December 31.
Jade Biosciences’ common stock is traded on the Nasdaq Capital Market under the ticker symbol JBIO.
Jade Biosciences has appointed Computershare as its stock transfer agent.
You can contact Computershare directly for assistance using one of the methods below:
- Online: www.computershare.com/investor
- Email: web.queries@computershare.com
- Phone (US, Canada, Puerto Rico): 1-800-736-3001
- Phone (International): 1-781-575-3100
- Mailing Address: Computershare Investor Services, P.O. Box 43078, Providence, RI 02940
- Overnight Delivery: Computershare Investor Services, 250 Royall Street, Canton, MA 02021
No, Jade Biosciences does not have a direct stock purchase plan or any similar program. Shares of Jade Biosciences' common stock can be purchased through any registered broker.
The CUSIP number for Jade Biosciences’ common stock is 008064206.
You can access all SEC filings at www.sec.gov by searching for “Jade Biosciences, Inc.” or using the ticker symbol JBIO. Filings are also available on the Investors section of JadeBiosciences.com.
Visit the Investors section of JadeBiosciences.com and submit your email to receive the latest updates and filings.
Email the Jade Investor Relations team at IR@JadeBiosciences.com.